42Stockpicking

BMY

Bristol Myers SquibbKøb· 74.1%· 25. aug. 2026
NYSE·Healthcare·USD

Henter pris…

Værdiansættelse (TTM)

P/Ei
19,6
36th %ile · 62p
EV/EBITDAi
—
P/Bi
7,5
71st %ile · 64p
P/Si
2,9
42nd %ile · 70p
EV/Salesi
3,8
51st %ile · 70p
Div yieldi
3,7 %
94th %ile · 39p

Kursudvikling

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 27.8.2026full
Prishistorik
30,3 år
Pris-dage
7629
Årsregnskaber
19
Peers
0/0
Valuation
5/6
Fundamentals
8/8
Datovindue
1996-04-30 til 2026-08-25

Blokkere

  • Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

  • Kør compute-multiples for manglende valuation metrics.

Seneste assessment

BMY vurderet 2026-08-27

Score
71.4%
Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

100%

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

80%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

89%

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

90%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

37%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

55%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

62%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: Own P/E 19.6 vs peer median 21.3; broadly in line with the peer set.

Insider activity

Net 90d (aktier)
-500
Net 90d (værdi)
-33.750 USD
Købere 90d
0
Cluster
—
DatoPersonRolleTypeAntalVærdiKilde
25.8.2026Holzer Phil MSVP and Controller▼ SALG-500-33.750 USDsec
1.8.2026Gallman CariEVP, General Counsel· ANDET-543-35.463 USDsec
1.8.2026Gallman CariEVP, General Counsel◆ OPT.1.061—sec
1.8.2026Massacesi CristianEVP,Chief Med Offr,Head of Dev◆ OPT.51.172—sec
1.8.2026Massacesi CristianEVP,Chief Med Offr,Head of Dev· ANDET-26.175-1.709.489 USDsec
15.6.2026Haller Julia A—◆ OPT.20.4601.099.930 USDsec
3.6.2026Short Bartie WendyEVP, Corporate Affairs· ANDET-3.876-212.095 USDsec
3.6.2026Short Bartie WendyEVP, Corporate Affairs◆ OPT.8.040—sec

Earnings

QuarterDateEPS actualEPS estEPS surpriseRevenue surprise
2026Q230.7.20262,041,60+27.7%+27.7%Beat
2026Q130.4.20261,581,42+11.2%+11.2%Beat
2025Q430.1.20261,261,20+4.6%+4.6%Inline
2025Q330.10.20251,631,52+7.5%+7.5%Beat
2025Q230.7.20251,461,10+32.6%+32.6%Beat